Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis

被引:41
作者
Ineichen, Benjamin, V [1 ,2 ]
Tsagkas, Charidimos [1 ,3 ,4 ,5 ,6 ,7 ]
Absinta, Martina [8 ,9 ,10 ]
Reich, Daniel S. [1 ]
机构
[1] NINDS, Translat Neuroradiol Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA
[2] Univ Zurich, Univ Hosp Zurich, Clin Neurosci Ctr, Dept Neuroradiol, Zurich, Switzerland
[3] Univ Hosp Basel, Dept Med, Neurol Clin & Policlin, Basel, Switzerland
[4] Univ Hosp Basel, Dept Clin Res, Neurol Clin & Policlin, Basel, Switzerland
[5] Univ Hosp Basel, Dept Biomed Engn, Neurol Clin & Policlin, Basel, Switzerland
[6] Univ Basel, Basel, Switzerland
[7] Univ Hosp Basel, Dept Med & Biomed Engn, Translat Imaging Neurol ThINk Basel, Basel, Switzerland
[8] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[9] Univ Vita Salute San Raffaele, Milan, Italy
[10] IRCCS San Raffaele Sci Inst, Neurol Unit, Milan, Italy
基金
瑞士国家科学基金会;
关键词
Multiple sclerosis; Leptomeningeal enhancement; Leptomeningeal inflammation; Magnetic resonance imaging; Systematic review; Meta-analysis; MRI FINDINGS; BRAIN; FLAIR; INFLAMMATION;
D O I
10.1016/j.nicl.2022.102939
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
Background: The lack of systematic evidence on leptomeningeal enhancement (LME) on MRI in neurological diseases, including multiple sclerosis (MS), hampers its interpretation in clinical routine and research settings. Purpose: To perform a systematic review and meta-analysis of MRI LME in MS and other neurological diseases. Materials and Methods: In a comprehensive literature search in Medline, Scopus, and Embase, out of 2292 publications, 459 records assessing LME in neurological diseases were eligible for qualitative synthesis. Of these, 135 were included in a random-effects model meta-analysis with subgroup analyses for MS. Results: Of eligible publications, 161 investigated LME in neoplastic neurological (n = 2392), 91 in neuroinfectious (n = 1890), and 75 in primary neuroinflammatory diseases (n = 4038). The LME-proportions for these disease classes were 0.47 [95%-CI: 0.37-0.57], 0.59 [95%-CI: 0.47-0.69], and 0.26 [95%-CI: 0.20-0.35], respectively. In a subgroup analysis comprising 1605 MS cases, LME proportion was 0.30 [95%-CI 0.21-0.42] with lower proportions in relapsing-remitting (0.19 [95%-CI 0.13-0.27]) compared to progressive MS (0.39 [95%-CI 0.30-0.49], p = 0.002) and higher proportions in studies imaging at 7 T (0.79 [95%-CI 0.64-0.89]) compared to lower field strengths (0.21 [95%-CI 0.15-0.29], p < 0.001). LME in MS was associated with longer disease duration (mean difference 2.2 years [95%-CI 0.2-4.2], p = 0.03), higher Expanded Disability Status Scale (mean difference 0.6 points [95%-CI 0.2-1.0], p = 0.006), higher T1 (mean difference 1.6 ml [95%-CI 0.1-3.0], p = 0.04) and T2 lesion load (mean difference 5.9 ml [95%-CI 3.2-8.6], p < 0.001), and lower cortical volume (mean difference -21.3 ml [95%-CI -34.7-7.9], p = 0.002). Conclusions: Our study provides high-grade evidence for the substantial presence of LME in MS and a comprehensive panel of other neurological diseases. Our data could facilitate differential diagnosis of LME in clinical settings. Additionally, our meta-analysis corroborates that LME is associated with key clinical and imaging features of MS.
引用
收藏
页数:18
相关论文
共 57 条
[1]  
Absinta M., 2020, CONTROVERSIAL ASS LE
[2]   Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases [J].
Absinta, Martina ;
Cortese, Irene C. M. ;
Vuolo, Luisa ;
Nair, Govind ;
de Alwis, Manori P. ;
Ohayon, Joan ;
Meani, Alessandro ;
Martinelli, Vittorio ;
Scotti, Roberta ;
Falini, Andrea ;
Smith, Bryan R. ;
Nath, Avindra ;
Jacobson, Steven ;
Filippi, Massimo ;
Reich, Daniel S. .
NEUROLOGY, 2017, 88 (15) :1439-1444
[3]   Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis [J].
Absinta, Martina ;
Vuolo, Luisa ;
Rao, Anuradha ;
Nair, Govind ;
Sati, Pascal ;
Cortese, Irene C. M. ;
Ohayon, Joan ;
Fenton, Kaylan ;
Reyes-Mantilla, Maria I. ;
Maric, Dragan ;
Calabresi, Peter A. ;
Butman, John A. ;
Pardo, Carlos A. ;
Reich, Daniel S. .
NEUROLOGY, 2015, 85 (01) :18-28
[4]   Differentiation of Leptomeningeal and Vascular Enhancement on Post-contrast FLAIR MRI Sequence: Role in Early Detection of Infectious Meningitis [J].
Ahmad, Armeen ;
Azad, Sheenam ;
Azad, Rajiv .
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2015, 9 (01) :TC8-TC12
[5]  
[Anonymous], 2015, BMJ-BRIT MED J, DOI [DOI 10.1136/BMJ.G7647, 10.4271/2015-01-1534]
[6]   Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder [J].
Asgari, Nasrin ;
Flanagan, Eoin P. ;
Fujihara, Kazuo ;
Kim, Ho Jin ;
Skejoe, Hanne P. ;
Wuerfel, Jens ;
Kuroda, Hiroshi ;
Kim, Su Hyun ;
Maillart, Elisabeth ;
Marignier, Romain ;
Pittock, Sean J. ;
Paul, Friedemann ;
Weinshenker, Brian G. .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2017, 4 (04)
[7]   Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study [J].
Bergsland, N. ;
Ramasamy, D. ;
Tavazzi, E. ;
Hojnacki, D. ;
Weinstock-Guttman, B. ;
Zivadinov, R. .
AMERICAN JOURNAL OF NEURORADIOLOGY, 2019, 40 (04) :620-625
[8]  
Bhargava P., 2021, BRAIN
[9]   Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement [J].
Bhargava, Pavan ;
Wicken, Cassie ;
Smith, Matthew D. ;
Strowd, Roy E. ;
Cortese, Irene ;
Reich, Daniel S. ;
Calabresi, Peter A. ;
Mowry, Ellen M. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 30 :136-140
[10]   Exploring the origins of grey matter damage in multiple sclerosis [J].
Calabrese, Massimiliano ;
Magliozzi, Roberta ;
Ciccarelli, Olga ;
Geurts, Jeroen J. G. ;
Reynolds, Richard ;
Martin, Roland .
NATURE REVIEWS NEUROSCIENCE, 2015, 16 (03) :147-158